Cargando…

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

Circulating antigen carbohydrate 125 (CA125) has emerged as a proxy of fluid overload in heart failure. This study aimed to evaluate the effect of dapagliflozin on short-term CA125 levels in patients with stable heart failure with reduced ejection fraction (HFrEF) and whether these changes mediated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amiguet, Martina, Palau, Patricia, Domínguez, Eloy, Seller, Julia, Pinilla, Jose Manuel Garcia, de la Espriella, Rafael, Miñana, Gema, Valle, Alfonso, Sanchis, Juan, Górriz, Jose Luis, Bayés-Genís, Antoni, Núñez, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313805/ https://www.ncbi.nlm.nih.gov/pubmed/37391470 http://dx.doi.org/10.1038/s41598-023-37491-5

Ejemplares similares

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum
por: Santas, Enrique, et al.
Publicado: (2021)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness
por: de la Espriella‐Juan, Rafael, et al.
Publicado: (2018)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO(2) study
por: Mora-Fernández, Carmen, et al.
Publicado: (2023)

Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
por: Núñez, Julio, et al.
Publicado: (2015)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure
por: Civera, Jose, et al.
Publicado: (2022)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
por: Miñana, Gema, et al.
Publicado: (2022)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Biomarkers to Improve Decision-making in Acute Heart Failure
por: de la Espriella, Rafael, et al.
Publicado: (2023)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome
por: Gabaldon-Perez, Ana, et al.
Publicado: (2021)

Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
por: del Canto, Irene, et al.
Publicado: (2022)

Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome
por: Núñez, Julio, et al.
Publicado: (2022)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Refractory congestive heart failure: when the solution is outside the heart
por: Pernias, Vicente, et al.
Publicado: (2019)

Peritoneal and Urinary Sodium Removal in Refractory Congestive Heart Failure Patients Included in an Ambulatory Peritoneal Dialysis Program: Valuable for Monitoring the Course of the Disease
por: Miñana, Gema, et al.
Publicado: (2023)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction
por: Domínguez, Eloy, et al.
Publicado: (2018)

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study
por: Núñez, Julio, et al.
Publicado: (2016)

Acute Coronary Syndromes in 2011 and 2012
por: Sanchis, Juan, et al.
Publicado: (2013)

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion
por: Rios-Navarro, Cesar, et al.
Publicado: (2018)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Sex differences on peak oxygen uptake in heart failure
por: Palau, Patricia, et al.
Publicado: (2019)

Heart Failure Treatment by Device
por: Bayés-Genis, Antoni
Publicado: (2020)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jmg2nopn4doogl81jkro2amv1k